Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada

• Autores: Víctor Rossel, Felipe Díaz Toro, Hugo Verdejo, Roberto Concepción, Luis Sepúlveda, Pablo Castro, Jose L. Vukasovic, Angie Bernales
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 145, Nº. 6, 2017, págs. 734-740
• Idioma: español
• Títulos paralelos:
  • Galectin-3 levels in patients hospitalized for decompensated heart failure
• Enlaces
  • Texto completo
• Resumen

  • Background: Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 ± 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 ± 13.4%. Pro-BNP values at discharge were 5,323 ± 8,665 pg/mL. Gal-3 values were 23.8 ± 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 ±16 and 62 ± 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects.